Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IceCure Medical (ICCM) Total Non-Current Liabilities (2020 - 2025)

IceCure Medical (ICCM) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $13000.0 as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 91.93% to $13000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13000.0 through Dec 2025, down 91.93% year-over-year, with the annual reading at $13000.0 for FY2025, 91.93% down from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $13000.0 at IceCure Medical, down from $161000.0 in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $1.3 million in Q4 2021, with the low at $13000.0 in Q4 2025.
  • Average Total Non-Current Liabilities over 5 years is $456600.0, with a median of $376000.0 recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities skyrocketed 48.57% in 2021, then crashed 91.93% in 2025.
  • Over 5 years, Total Non-Current Liabilities stood at $1.3 million in 2021, then plummeted by 67.0% to $430000.0 in 2022, then fell by 12.56% to $376000.0 in 2023, then tumbled by 57.18% to $161000.0 in 2024, then plummeted by 91.93% to $13000.0 in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $13000.0, $161000.0, and $376000.0 for Q4 2025, Q4 2024, and Q4 2023 respectively.